Evolent Clinical Guideline 3015 for Lunsumio™ and Lunsumio Velo™ (mosunetuzumab-axgb IV/SC)

Guideline Number: Evolent_CG_3015	**Applicable Codes**	
"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc. ***© 2023 - 2026 Evolent. All rights Reserved.***		
Original Date: February 2023	**Last Revised Date:** February 2026	**Implementation Date:** February 2026

TABLE OF CONTENTS

STATEMENT **2**
PURPOSE 2
INDICATIONS **2**
FOLLICULAR LYMPHOMA (FL) 2
CONTRAINDICATIONS/WARNINGS **2**
EXCLUSION CRITERIA **3**
CODING AND STANDARDS **4**
CODES 4
APPLICABLE LINES OF BUSINESS 4
POLICY HISTORY **4**
LEGAL AND COMPLIANCE **5**
GUIDELINE APPROVAL 5
Committee *5*
DISCLAIMER 5
REFERENCES **5**

STATEMENT

Purpose

To define and describe the accepted indications for Lunsumio and Lunsumio Velo (mosunetuzumab-axgb IV/SC) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Follicular Lymphoma (FL)

- Lunsumio and Lunsumio Velo (mosunetuzumab-axgb IV/SC) may be used as monotherapy for adult members with CD20 positive follicular lymphoma that has relapsed after or failed to respond to at least two prior lines of systemic therapy, including an anti-CD20-directed therapy (e.g. rituximab/rituximab biosimilars, obinutuzumab) and an alkylating agent (e.g. bendamustine, cyclophosphamide). This indication excludes members with histologic transformation of follicular lymphoma to diffuse large B-cell lymphoma.

CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
    - Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving mosunetuzumab-axgb. Initiate treatment with the mosunetuzumab-axgb step-up dosing schedule to reduce the risk of CRS. Withhold mosunetuzumab-axgb until CRS resolves or permanently discontinue based on severity.

EXCLUSION CRITERIA

- Disease progression while taking Lunsumio and Lunsumio Velo (mosunetuzumab-axgb IV/SC).
- Concurrent use with other anticancer therapies.
- Diagnosis of Follicular Lymphoma that has transformed to Diffuse Large B-Cell Lymphoma.
- Dosing exceeds single dose limit of Lunsumio (mosunetuzumab-axgb IV) 60 mg (with cycles 1 and 2 step-up dosing protocol) and 30 mg (cycle 3 and beyond).
- Dosing exceeds single dose limit of Lunsumio Velo (mosunetuzumab-axgb SC) 45 mg.
- Treatment exceeds the maximum months duration limit of 8 cycles (if patients achieved a complete response) or up to 17 cycles (for partial response or stable disease after the initial 8 cycles).
- Investigational use of Lunsumio and Lunsumio Velo (mosunetuzumab-axgb IV/SC) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
    - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
    - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
    - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
    - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
    - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
    - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
    - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J9350 - Injection, mosunetuzumab-axgb, 1 mg
- J9350 - Injection, mosunetuzumab-axgb, for subcutaneous use

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
February 2026	• Added "Lunsumio Velo (mosunetuzumab-axgb)" to all relevant sections • Updated contraindications/warnings section • Updated exclusion criteria • Updated references
February 2025	• Converted to new Evolent guideline template • This guideline replaces UM ONC_1474 Lunsumio (mosunetuzumab-axgb)
February 2024	• Updated exclusion criteria • Updated NCH verbiage to Evolent • Updated "continuation request" verbiage

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Budde LE, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7.
2. Lunsumio prescribing information. Genentech, Inc. South San Francisco, CA 2025.
3. Lunsumio Velo prescribing information. Genentech, Inc. South San Francisco, CA 2025.
4. Clinical Pharmacology Elsevier Gold Standard 2026.
5. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2026.
6. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2026.
7. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2026.
8. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
9. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf.
10. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.